We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
- Authors
Krivak, Thomas C; Darcy, Kathleen M; Tian, Chunqiao; Armstrong, Deborah; Baysal, Bora E; Gallion, Holly; Ambrosone, Christine B; DeLoia, Julie A; Gynecologic Oncology Group Phase III Trial
- Abstract
We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 21, p3598
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.16.1323